Amgen Inc. is paying $3.7 billion in cash to buy Chemocentryx Inc. The deal, with Amgen paying $52 per share for Chemocentryx stock, brings Amgen Tavneos (avacopan), a first-in-class medicine for treating antineutrophil cytoplasmic antibody-associated vasculitis, which destroys small blood vessels. Read More
Gilead Sciences Inc. has bought the privately owned U.K. biotech Mirobio Ltd., paying $405 million for the Oxford-based firm and its checkpoint agonists to treat autoimmune diseases. Foster City, Calif.-based Gilead will gain Mirobio’s discovery platform and entire portfolio of immune inhibitory receptor agonists. Read More
F2G Ltd. has raised a further $70 million in venture capital as it continues preparations to submit a new drug application to the U.S. FDA for its novel antifungal drug, olorofim, before the end of 2022. Read More
Sironax Ltd. has raised $200 million in a series B financing round to support the development of its receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors. The latest financing has brought the capital raised by the Beijing and Shanghai-based company to more than $300 million to date. Read More
With data due later this summer from the phase II Pioneer trial testing Blueprint Medicines Corp.’s approved Ayvakit (avapritinib), many investor eyes are on the potential label expansion into indolent systemic mastocytosis – but the company has another potential ace in the hole with BLU-451, which targets EGFR exon 20 insertion mutations in non-small-cell lung cancer (NSCLC). Read More
Amylyx Pharmaceuticals Inc. got good news when the Institute for Clinical and Economic Review posted a revised evidence report Aug. 4 that assessed the comparative clinical effectiveness and value of the company’s AMX-0035 and Mitsubishi Tanabe Pharma America Inc.’s Radicava (edaravone) in treating amyotrophic lateral sclerosis. Read More
The amount of money raised by biopharma companies so far this year is down by 59% in comparison with last year, and there are 42% fewer transactions. Read More
Makers of biotech therapies and in vitro diagnostics may be understandably weary of hearing about patent subject matter eligibility under Section 101 of the Patent Act, but Sen. Thom Tillis (R-N.C.) is prepared to take another swipe at the problem. Tillis announced Aug. 3 that the Patent Eligibility Restoration Act of 2022 is intended to reverse some of the deleterious effects of U.S. Supreme Court jurisprudence on Section 101 questions, a proposal that may be the last, best chance to address what many believe is a fundamentally broken judicial understanding of subject matter eligibility. Read More
Please take a few minutes to fill out this short survey to help us provide you with the best possible source of news. Customer feedback is critical so that we can make BioWorld a valuable component of your daily workflow. We want to continue to evolve to serve you. The survey should take just 5 minutes. You can click through to the questions here. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: AC Immune, Acurx, Aerie, Alnylam, Antengene, Cardiol, Cassava, Cornerstone, Helixmith, Innocare, Kazia, Kintor, Landos, Merck & Co., Merrimack, Regeneron, Sciwind, Sorrento, ST Pharm, Tevogen, TME, Vaxess. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Ampio, Eureka, Mymd, Tikomed, Xenetic, Zyversa. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amylyx, Anheart, Ascletis, Avenge, Biontech, Coherus, Jiangsu Recbio, Lynk, Maia, Marius, Mediwound, Olix, Pfizer, Profoundbio, Regenxbio, Renovion, Sinovac, Sumitomo. Read More
